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T 
he  article  by Hirota  et  al.  (pp.  2627-2634)  provides 
interesting  evidence  for  the  action  of Interleukin-6 
(IL-6) in the nervous system, but is it appropriate to con- 
sider IL-6 a neurotrophic factor; and, if so, what does this 
mean?  The  last  decade  has  seen  the  discovery of a  large 
number of neurotrophic  and neural  differentiation  factors 
in both the peripheral and central nervous system. Exam- 
ples  of peptides  with  interesting  activities in  the  nervous 
system  include  BDNF,  NT-3,  CNTF,  GDNF,  bFGF, 
aFGF,  IL-3, IL-2, LIF, and others.  The molecular charac- 
terization  of growth factors has led to  the  realization  that 
these peptides can play different roles in the nervous system 
and that they can also  play important roles in many other 
tissues. 
Over the last  40 years, studies of Nerve Growth Factor 
(NGF), which is the prototypic growth factor, have dem- 
onstrated that NGF plays a central role in the development 
and survival of neurons from both the peripheral and cen- 
tral  nervous  system.  NGF  functions  as  a  target  derived 
trophic factor, i.e.,  a factor that is derived from an inner- 
vated tissue that is essential for the survival of the innervat- 
ing  neuron.  Competition  for  trophic  factors,  which  are 
thought to be in limiting supply, is believed to be a major 
cause of apoptotic cell death, a feature of almost every de- 
veloping neuronal population. Over the past few years, stud- 
ies  using  gene  disruption  approaches  (1)  have  confirmed 
and  extended  the  classic  immunosympathectomy experi- 
ments (2) that used antibodies directed against NGF to show 
its  importance in  the  development of the  peripheral ner- 
vous system. 
More  recently,  functional  NGF  receptors  have  been 
documented in T  cells, B cells and mast cells  (e.g., see ref- 
erences 3, 4, 5, and references therein). Both NGF and IL-6 
affect stromal cells in the thymus and may participate in a 
neuromodulatory loop (6).  These experiments support the 
possibility that peptide growth factors could mediate inter- 
actions both within and, possibly, between the nervous sys- 
tem and the immune system. 
Another class of peptides important in the development 
of the nervous system were originally studied because they 
served an instructional  rather than a survival role.  For ex- 
ample,  the  developing  sympathetic  nerve  expresses  both 
cholinergic  and  adrenergic  characteristics,  but  during  the 
process  of innervation,  the  choice  of neurotransmitter  is 
fixed in a process that depends on the target of innervation 
(for reviews see references 7, 8). A similar change has been 
shown to occur in cultured sympathetic neurons.  This al- 
lowed investigators to purl@ the environmental factors that 
could participate in this switching event. These studies led 
to  the  purification  of the  first  cholinergic  differentiation 
factor (CDF), which, surprisingly, was identical to the pre- 
viously  described  Leukemia  Inhibitory  Factor  (LIF)  (9). 
While  there is no doubt that CDF/LIF can influence  the 
expression  of classic  neurotransmitters  and neuropeptides, 
studies with mice deficient in the expression of this peptide 
demonstrate that it is not essential for determining neuronal 
phenotype in all  cases.  Interestingly,  CDF/LIF is induced 
during  neural  injury  and  can rescue  motor neurons  from 
axotomy induced  cell  death,  blurring  the  distinction  be- 
tween trophic (i.e., survival) and instructive factors (10,  11). 
CDF/LIF is homologous to ciliary neuronotrophic  fac- 
tor  (CNTF),  which  was  purified  as  a  survival factor for 
cholinergic neurons in the peripheral nervous system, but it 
may also play a role in the central nervous system (12,  13). 
The  timing  of the  expression  of this  protein,  however, 
makes it obvious that it could not function  as an essential 
target derived trophic factor (14).  Both CNTF and LIF are 
homologous to IL-6, a peptide that was isolated as a factor 
that stimulates B  cell differentiation into  immunoglobulin 
secreting cells.  There is, however, emerging evidence that 
IL-6 has roles both in the immune function  and the ner- 
vous system. All three factors use gp130 as part of their cell 
surface receptor. 
The discovery that IL-6 was expressed in astrocytes led 
to speculation that it might play a role in the nervous sys- 
tem (15).  Initial studies demonstrated that IL-6 could stim- 
ulate  the  differentiation of PC12  cells  as demonstrated by 
the elaboration of neurites (i.e., long nerve-like processes), 
the development of action potentials, and the expression of 
a number of neuronal markers. All  of these  are responses 
that are also controlled by classic  neurotrophic factors like 
NGF. Furthermore, IL-6 activates many of the same intra- 
cellular signaling events that are activated by NGF (16,  17). 
These initial observations inspired the search for other roles 
for this growth factor in the nervous system. 
Since one of the hallmarks oftrophic factors is their ability 
to promote neuron survival, a number of studies of the pro- 
tective effects of IL6 have been done.  IL-6 protects dopa- 
minergic neurons  against MPP+  (1-methyl-4-phenylpyri- 
dinium) toxicity (18) and the development of a Parkinson- 
like  syndrome,  and  it  protects  strlatal  neurons  against 
NMDA (N-Methyl-D-Aspartate), a neurotoxic glutamate an- 
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hance  the  survival  of several  classes  of neurons  in  culture 
(20, 21). 
IL-6  alone  is  not  capable  of stimulating  neurite  out- 
growth from cells in the peripheral  nervous system, which 
is surprising  since  the  PC12  line  mostly resembles  an  un- 
committed  sympathetic  nerve.  However,  IL-6  can  influ- 
ence the expression of neurotransmitter  enzymes, which is 
consistent  with  its  structural  and  functional  homology to 
LIF/CDF  (22).  IL-6 and its  receptor have been shown to 
be  induced  in  response  to  neural  injury,  again  suggesting 
that IL-6 is part of a coordinated response to injury in the 
adult (23, 24). 
The  paper  by  Hirota  and  colleagues  in  this  issue  (pp. 
2627-2634)  makes  several  important  contributions  to this 
emerging story.  First,  it demonstrates  that the failure  of at 
least some sensory nerves to respond to IL-6 is the lack of 
the  IL-6 receptor.  Presumably,  IL-6 and  the  soluble  form 
of the IL-6 receptor interact and activate the gp130 recep- 
tor as a complex. Thus, the addition of the soluble IL-6 re- 
ceptor allows these cells to respond to IL-6. This observa- 
tion parallels  the  effectiveness  of the  combination  of IL-6 
and  its  receptor in several  other  systems  (25).  This  some- 
what  unusual  situation  has been  described  mechanistically 
as a two chain receptor model (26); but it also has interest- 
ing  biological  implications  which  merit  future  consider- 
ation.  The failure  of a neuron to express the IL-6 receptor 
under normal  circumstances would allow them to  express 
gp130, which also serves as a receptor for CNTF and LIF, 
allowing them to retain responsiveness to these growth fac- 
tors.  It provides an insight into the striking similarity of the 
effects of CNTF, LIF/CDF and IL-6 as well as an interest- 
ing  explanation  of the  differences  among  these  peptides. 
The involvement of a second receptor subunit in defining 
receptor specificity is reminiscent of the role of p75 in mod- 
ulating the specificity of the NGF receptor (27). 
Several peptide growth factors, including NGF and FGF 
have been shown to enhance peripheral nerve regeneration, 
and since IL-6 acts by a different receptor class there is an ex- 
citing possibility for synergistic stimulation  of regeneration 
and regain of physiological function. Likewise,  IL-6/IL-6P, 
or related growth factors might provide trophic support for 
neurons in a variety of neurodegenerative diseases  (28). 
As in the case of the LIF and CNTF,  the capability of a 
peptide to regulate a particular biological response does not 
necessarily mean  that it does so in vivo.  In this paper,  the 
biological relevance of IL-6's in vitro activity was strength- 
ened by the  demonstration  that antibody to IL-6R inhib- 
ited regeneration.  This suggests that endogenous activity of 
this  pathway  promotes  regeneration.  Furthermore,  nerve 
injury also increased the  expression  of IL-6P, in the  dam- 
aged nerve making it more likely to be responsive to IL-6. 
Likewise, there is an increase in the expression oflL6 in the 
supporting Schwann cells.  Nerve injury also enhances pro- 
duction of NGF in Schwann cells,  indicating that they are 
capable  of providing several  classes  of trophic  support.  In 
the  context  of studies  with  the  clonal  lines  cited  above, 
there is a strong case for the direct action of IL-6 on regen- 
erating neurons, although the possibility that there is an in- 
termediate cell still  exists. 
Does IL-6 also play a role in normal development? Does 
it function as a target derived neurotrophic factor? Current 
studies  make  this  a pressing  question.  Studies  of its  spatial 
and  temporal  expression  during  development  should pro- 
vide circumstantial evidence of whether it might participate 
in  the  regulation  of apoptotic  death  during  development, 
or  is  more  likely  to  be  involved  in  an  injury  response. 
More definitive studies will require the use of animals with 
disrupted genes to determine if aberrant expression of IL-6 
and/or  its  receptor  effects  neural  development.  A  persua- 
sive case can be made that it might be quite productive to 
determine the trophic effects of related cytokines including 
Oncostatin M, which has not yet been studied.  Alterations 
that might be expected could be confined to details of neu- 
ral phenotype, but may extend to neuronal survival. 
Perhaps  one  of the  most intriguing  questions  raised  by 
these discoveries is whether the presence of common com- 
ponents of cell-cell signaling pathways in the  nervous sys- 
tem and the immune system points to a nmtual interdepen- 
dence  of these  systems during  neural  regeneration.  Nerve 
regeneration is a complex process that involves the partici- 
pation of cells  from the immune system.  In the peripheral 
nervous system, macrophages play an important role in the 
regenerative  process.  Does  the  expression  of IL-6 play  a 
role  in  modulating  the  participation  of the  immune  re- 
sponse in regeneration or is it more appropriately viewed as 
an example of the use of the same signaling components in 
two  systems? There  is  no  doubt  that  the  study of the  in- 
volvement  of cytokines  in  neural  development  will  con- 
tinue to be fruitful avenue of exploration. 
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